Your session is about to expire
← Back to Search
CC-92480 + Dexamethasone for Multiple Myeloma
Study Summary
This trial is testing a new way to treat Multiple Myeloma that has relapsed or become refractory to other treatments. The trial will assess the safety and efficacy of the new treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 4 trial • 122 Patients • NCT01474915Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My myeloma worsened within 2 months after my last treatment.I have had a bone marrow transplant from another person.I have moderate to severe nerve damage.I had major surgery recently.I can take care of myself and am up and about more than half of my waking hours.I have had cancer before, but not multiple myeloma, under certain conditions.You are allergic to the ingredients in CC-92480 or dexamethasone.I have heart problems that affect my daily activities.I have been diagnosed with amyloidosis or POEMS Syndrome.My last treatment for myeloma was CAR-T therapy, and my disease has progressed since.You need to have certain test results from your blood work.I am following the required pregnancy prevention measures.I am following the required contraception guidelines.I am currently receiving treatment for another type of cancer.I have an active chronic hepatitis B or C infection.I have been treated for myeloma with specific drugs recently.I cannot or do not want to follow the required blood clot prevention treatment.I am 18 years or older and can sign the consent form.I have taken immunosuppressive drugs within the last 14 days.My multiple myeloma does not produce detectable levels of M protein.I am HIV positive.I have had a medical procedure within 2 weeks before starting CC-92480.My condition hasn't improved after taking certain medications.I have a stomach or intestine condition that affects how my body absorbs medication.I have undergone 3 or more treatments for myeloma, including specific medications.My multiple myeloma has not responded to treatment.I agree not to donate blood while on CC-92480 and for 28 days after stopping it.I have been diagnosed with multiple myeloma and it can be measured.I have IgM myeloma.I have plasma cell leukemia or active leptomeningeal myelomatosis.I am currently receiving dialysis.
- Group 1: Administration of CC-92480 in combination with dexamethasone
- Group 2: Administration of CC-92480 monotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the recruitment phase of this trial still open?
"As per clinicaltrials.gov, this research endeavour is actively recruiting participants. The trial was initialy advertised on February 6th 2018 and underwent a recent update on October 25th 2022."
To what ailments does CC-92480 most commonly provide therapeutic relief?
"CC-92480 is mostly employed to treat ophthalmia, sympathetic. Additionally, it has been observed that this pharmaceutical can have a beneficial effect on conditions like branch retinal vein occlusion and macular edema."
Could you enumerate the research undertaken regarding CC-92480?
"The initial research into CC-92480 took place back in 2002 at Manitoba Blood & Marrow Transplant Program CancerCare Manitoba. Since then, 1111 trials have been completed, and there are currently 552 ongoing studies; many of these being conducted out of New york City."
What are the major goals for this clinical exploration?
"This 28-day trial seeks to evaluate the pharmacokinetic half-life of an investigational drug. Secondary analysis will consider time from first response (≥ PR) until progression or death, time from the initial dose to a partial response and overall response rate according to IMWG Uniform Response Criteria."
How many research centers are currently implementing this trial?
"Memorial Sloan Kettering Cancer Center in New york, Roswell Park in Buffalo and University Of Virginia in Charlottesville are amongst the 25 recruiting centres for this clinical trial. The other locations have similarly been selected to ensure a wide range of patient participation."
What is the total enrollment number for this experimental research?
"Affirmative. Clinicaltrials.gov has records of this trial being initiated on February 6th 2018 and recently updated on October 25th 2022, presently looking for 201 participants at twenty-five locations."
Share this study with friends
Copy Link
Messenger